Get informed when a big investor buys or sells
+ FollowOvervalued by 103.5% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $707,025.00 |
|---|---|
| Enterprise Value | $731,968.00 |
| Earnings per Share | $0 |
| Beta | 1.58 |
| Outstanding Shares | 44,944,916 |
| P/E Ratio | -5.71 |
|---|---|
| PEG | 25.98 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | 7624.67 |
| Enterprise Value to EBIT | -4.33 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.35 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Mushrooms, Inc. is a biotechnology company that develops products from mushrooms and mycelium. The company focuses on mycelium's industrial applications for carbon-neutral products, health supplements, and technologies for healthcare and...